Velcheti V, Rai P, Kao YH, et al. 5-year real-world outcomes with frontline pembrolizumab monotherapy in PD-L1 expression ≥ 50% advanced NSCLC [J]. Clin Lung Cancer. 2024;25(6):502-508.e3

Article  CAS  PubMed  Google Scholar 

Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells[J]. J Exp Med. 1996;183(6):2533–2540

Article  CAS  PubMed  Google Scholar 

Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway [J]. N Engl J Med. 2016;375(18):1767–1778

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng C, Huang S, Lin M, et al. Hepatotoxicity of immune checkpoint inhibitors: what is currently known [J]. Hepatol Commun. 2023;7(3):e0063

Article  PubMed  PubMed Central  Google Scholar 

Remash D, Prince DS, McKenzie C, et al. Immune checkpoint inhibitor-related hepatotoxicity: a review [J]. World J Gastroenterol. 2021;27(32):5376–5391

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis [J]. JAMA Oncol. 2018;4(12):1721–1728

Article  PubMed  PubMed Central  Google Scholar 

Miah A, Tinoco G, Zhao S, et al. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival [J]. J Cancer Res Clin Oncol. 2022;149:2235–2242

Article  PubMed  PubMed Central  Google Scholar 

Yin K. Influence factors and prediction model of immune-mediated hepatotoxicity in patients with malignant melanoma treated with pembrolizumab [J]. Chin J New Drugs Clin Rem. 2022;41(8):490–494

Google Scholar 

Jing Y, Zhang Y, Wang J, et al. (2021) Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy [J]. JNCI. 113(10): 1396–1404.

Chen P, Zhu J, Xu Y, et al. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database [J]. BMC Nephrol. 2023;24(1):107

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [J]. Int J Surg. 2021;88: 105906

Article  PubMed  Google Scholar 

Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors[J]. Ann Intern Med. 2013;158(4):280–286

Article  PubMed  Google Scholar 

Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–436

Article  CAS  PubMed  Google Scholar 

Samani A, Zhang S, Spiers L, Suwaidan AA, Merrick S, Tippu Z, et al. Impact of age on the toxicity of immune checkpoint inhibition. J Immunother Cancer. 2020;8(2):e000871

Article  PubMed  PubMed Central  Google Scholar 

Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, et al. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. Eur J Cancer. 2020;129:71–79

Article  CAS  PubMed  Google Scholar 

Huang X, Tian T, Zhang Y, Zhou S, Hu P, Zhang J. Age-associated changes in adverse events arising from anti-PD-(L)1 therapy. Front Oncol. 2021;11:619385

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wong SK, Nebhan CA, Johnson DB. Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy. Front Immunol. 2021;12:786046

Article  CAS  PubMed  PubMed Central  Google Scholar 

Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017;22(8):963–971

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system [J]. Nat Immunol. 2018;19(1):10–19

Article  PubMed  Google Scholar 

Huff WX, Kwon JH, Henriquez M, et al. The evolving role of CD8+ CD28− immunosenescent T cells in cancer immunology[J]. Int J Mol Sci. 2019;20(11):2810

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valpione S, Pasquali S, Campana LG, Piccin L, Mocellin S, Pigozzo J, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16(1):94

Article  CAS  PubMed  PubMed Central  Google Scholar 

Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050

Article  PubMed  Google Scholar 

Triggianese P, Novelli L, Galdiero MR, Chimenti MS, Conigliaro P, Perricone R, et al. Immune checkpoint inhibitors-induced autoimmunity: the impact of gender. Autoimmun Rev. 2020;19(8):102590

Article  CAS  PubMed  Google Scholar 

Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018;9:2279

Article  PubMed  PubMed Central  Google Scholar 

Kocheise L, Piseddu I, Vonderlin J, et al. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease [J]. Front Immunol. 2024;14:1326078

Article  PubMed  PubMed Central  Google Scholar 

Michailidou D, Khaki AR, Morelli MP, et al. Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci Rep. 2021;11(1):9029

Article  CAS  PubMed  PubMed Central  Google Scholar 

Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21–29

Article  CAS  PubMed  Google Scholar 

Haanen J, Ernstoff M, Wang Y, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer. 2020;8(1):e000604

Article  PubMed  PubMed Central  Google Scholar 

Pan J, et al. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Exp Opin Drug Safe. 2022;21(10):1275–1287

Article  CAS  Google Scholar